Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Corvidia Stock

Q: How to sell Corvidia stock?

If you hold private company shares of Corvidia - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Corvidia stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

corvidiatx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $91.8MM

Corvidia Therapeutics is a developer of precision therapies using the science of genomics in new ways.

Buy or sell Corvidia stockLearn more about Corvidia IPO

OverviewFinancingsValuation

Enterprise Value

Access Corvidia’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Corvidia.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Nicholas Coscia

Controller

GaoZhong Zhu

Vice President & Head of Pharmaceutical Development and Manufacturing

Marc de Garidel

Chief Executive Officer & Board Member

Matt Devalaraja Ph.D

Co-Founder, Executive Vice President & Head of Research & Development

Douglas Kling

Senior Vice President, Clinical Operations

Michael Davidson MD

Co-Founder, Board Member & Chief Scientific Officer

Ram Aiyar Ph.D

Co-Founder, Executive Vice President & Head of Business Development

Kurt Herzog

Senior Business Analyst

Board Members

Aaron Kantoff

Apple Tree Partners

Marc de Garidel

Sylvie Grégoire Ph.D

Graziano Seghezzi Ph.D

Sofinnova Partners

Michael Davidson MD

Karim Helmy Ph.D

Venrock

Seth Harrison MD

Apple Tree Partners

Tyrell Rivers Ph.D

Corvidia stock FAQs

Can you buy Corvidia stock?

As Corvidia is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Corvidia, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Corvidia stock?

To invest in a private company like Corvidia through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Corvidia stock?

Yes, you may be able to sell your Corvidia stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Corvidia stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Corvidia stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Corvidia a public company?

No, Corvidia is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Corvidia’s stock price?

Corvidia is a privately held company and therefore does not have a public stock price. However, you may access Corvidia’s private market stock price with Forge Data.

What is Corvidia’s stock ticker symbol?

Corvidia does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

PR Newswire 01/08/2020

Corvidia Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in...

FinSMEs 02/17/2016

Corvidia Therapeutics Raises $26M in Series A Funding |FinSMEs

Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding. The round was co-led by Sofinnova Partners and Apple Tree Partners. In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi, Partner at Sofinnova …

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.